Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

PDS Biotechnology Corp

NASDAQ: PDSB · Life Sciences · 8 alerts · CIK 1472091

Share price
$0.9241Close, Nov 16
Market cap
$97M
Shares outstanding
105.01MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PDS Biotechnology Corp filings on SEC EDGAR ↗

8:05 AM ET 8-K
Financial Results

PDS Biotechnology Financial Results

PDS Biotechnology reported third quarter 2026 financial results, highlighting a strategic shift to PDS0301 as its lead development program. The company also noted the initial closing of a $22.3 million PIPE financing led by Nant Capital and the appointment of several new board members, including Dr. Patrick Soon-Shiong.

“During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program. We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.”

Frank Bedu-Addo, PhD, President and Chief Executive Officer
8:06 AM ET 8-K
Capital Raise

PDS Biotechnology Capital Raise of $3.9M

NantWorks exercised outstanding common stock warrants to purchase 17,699,115 shares of PDS Biotechnology at an exercise price of $0.22 per share. The transaction generated approximately $3.9 million in gross proceeds for the company. PDS Biotech intends to use the funds to advance its PDS0301 program toward a Phase 3 trial in metastatic colorectal cancer and for general corporate purposes.

Value
$3.9M
Counterparty
NantWorks
6:02 AM ET 8-K
Investor Presentation

PDS Biotechnology Investor Presentation

PDS Biotechnology updated its corporate presentation deck for October 2026, providing an overview of its oncology drug development programs. The presentation includes updates on its Versamune-based product candidates, including PDS0101 and PDS0301, and discusses the company's research and development strategy.

8:01 AM ET 8-K
Leadership Change

PDS Biotechnology Leadership Change

PDS Biotechnology announced a significant board reconstitution with the immediate resignation of four directors (Kamil Ali-Jackson, Stephen Glover, Gregory Freitag, and Otis Brawley) and the appointment of three new directors: Deborah A. Ramsdell, John A. Dawson CBE, and Bruce Wendel. The new appointees bring extensive experience in drug development, commercialization, and regulatory affairs as the company prepares for Phase 3 trials of PDS0301.

8:06 AM ET 8-K
Clinical Trial Data

PDS Biotechnology Clinical Trial Data

PDS Biotechnology announced it will host a virtual Key Opinion Leader (KOL) event on October 15, 2026, to discuss clinical outcomes from the PDS0301 Phase 2 trials. The event will focus on the metastatic colorectal cancer (mCRC) cohort, specifically patients with unresectable microsatellite stable (MSS) liver metastases, a population where immunotherapy has historically been ineffective.

Counterparty
National Cancer Institute
8:05 AM ET 8-K
Clinical Trial Data

PDS Biotechnology Clinical Trial Data

PDS Biotechnology announced the publication of Phase 2 VERSATILE-002 trial results in JAMA Oncology, evaluating PDS0101 in combination with pembrolizumab for HPV16-positive head and neck cancer. The study reported a median overall survival of 39.3 months in ICI-naïve patients, significantly exceeding the 17.9 months typically seen with standard-of-care pembrolizumab. The treatment was well-tolerated with a 13.8% rate of Grade 3 or higher treatment-related adverse events.

Counterparty
JAMA Oncology
4:06 PM ET 8-K
Investor Presentation

PDS Biotechnology Investor Presentation

PDS Biotechnology Corporation filed an updated corporate presentation deck as an exhibit to its 8-K. The presentation provides an overview of the company's oncology drug development programs, including PDS0101 and PDS0301, as of September 2026. This filing serves as a strategic update for investors regarding the company's clinical trial pipeline and research collaborations.

4:11 PM ET 8-K
Capital Raise

PDS Biotechnology Capital Raise of $11.3M

PDS Biotechnology completed the initial closing of a PIPE financing led by Nant Capital, raising $11.3 million in gross proceeds through the sale of common stock and warrants. The company also announced a contingent milestone closing for an additional $11 million and appointed Dr. Patrick Soon-Shiong and James Banaag to its Board of Directors. Proceeds will be used to repay $4.6 million in debt to Yorkville and advance the PDS0301 clinical program.

Value
$11.3M
Counterparty
Nant Capital, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.